Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
On February 28, 2025, Michael Bavaro, Chief Human Resources Officer of Option Care Health, Inc. (NASDAQ:OPCH), executed a significant stock sale. Bavaro sold 30,996 shares of common stock at a weighted average price of $33.2573 per share, generating approximately $1.03 million in proceeds. The transaction comes as Option Care Health, with a market capitalization of $5.63 billion, trades near its 52-week high of $34.57. According to InvestingPro analysis, the stock’s technical indicators suggest overbought conditions. The sale occurred in multiple transactions with prices ranging from $33.25 to $33.285 per share.
In addition to the sale, Bavaro exercised several stock options, acquiring a total of 15,739 shares at various prices between $18.97 and $28.86. These exercises resulted in a total transaction value of approximately $374,783. Following these transactions, Bavaro holds 44,974 shares of the company directly.
In other recent news, Option Care Health reported impressive financial results for Q4 2024, with earnings per share (EPS) of $0.44, surpassing analyst forecasts of $0.35. The company’s revenue reached $1.35 billion, exceeding expectations of $1.27 billion, marking a 19.7% increase year-over-year. Analysts from Truist Securities have raised the company’s stock target to $40, maintaining a Buy rating, citing strong core demand trends and attractive growth opportunities. The company’s strong free cash flow is expected to support ongoing mergers and acquisitions, as well as share repurchase initiatives. Option Care Health expanded its operations with new pharmacies and practitioner models, contributing to its robust performance. The firm also announced a $250 million stock repurchase, which bolstered investor sentiment. Looking ahead, Option Care Health projects 2025 revenue between $5.3 billion and $5.5 billion, with adjusted EBITDA ranging from $450 million to $470 million. Despite potential challenges from the Stelara biosimilar market dynamics, the company remains optimistic about its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.